FULC – fulcrum therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Form 4 Fulcrum Therapeutics, For: Nov 19 Filed by: Gould Robert J
Form 144 Fulcrum Therapeutics, Filed by: Gould Robert J
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
Form 10-Q Fulcrum Therapeutics, For: Sep 30
Form 8-K Fulcrum Therapeutics, For: Oct 29
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.